Why Intersect ENT is an Example of Hope for the Medtech Industry
Apr 26, 2013•38 min
Episode description
The 2.3% medical device tax is burdensome. Regulatory timelines are long (and expensive). Reimbursement is not only decreasing, but also incredibly hard to obtain. Venture capitalists are losing interest in early stage medical device deals. Is it all downhill for medtech? There is no doubt the current healthcare environment is challenging. But certainly not impossible...[read more]
Related Articles
For the best experience, listen in Metacast app for iOS or Android
